LINC00402: A Drug Target / Disease Biomarker (G100507612)

Target Name: LINC00402

NCBI ID: G100507612

LINC00402

Other Name(s): long intergenic non-protein coding RNA 402 | Long intergenic non-protein coding RNA 402

LINC00402: A Drug Target / Disease Biomarker

LINC00402 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and is involved in the development, maintenance, and progression of various diseases, including cancer.

LINC00402 is a small non-coding RNA molecule that is approximately 200 amino acids long. It is expressed in a variety of tissues and cells and is involved in the regulation of the cell cycle, which is the process by which cells grow, divide, and replicate their genetic material.

One of the key functions of LINC00402 is to regulate the length of telomeres, which are the protective caps at the end of chromosomes that help to prevent chromosomes from fusing with one another. Telomeres are naturally shortened each time a cell divides, and the length of telomeres can be affected by a variety of factors, including the age of the cell, the environment, and the presence of certain diseases.

LINC00402 has been shown to play a key role in the regulation of telomere length. Studies have shown that LINC00402 is a negative regulator of telomere elongation and that it promotes the shortening of telomeres. This means that when telomeres are shortened, LINC00402 is activated and works to reverse the process and lengthen the telomeres.

In addition to its role in telomere regulation, LINC00402 has also been shown to be involved in a variety of other cellular processes. For example, it has been shown to play a role in the regulation of gene expression, cell adhesion, and cell signaling.

Given its involvement in so many cellular processes, LINC00402 is a promising drug target and biomarker. Studies have shown that LINC00402 is highly conserved across different species and that it is expressed in a variety of tissues and cells. This makes it a potential target for small molecules, antibodies, or other therapeutic agents that can modulate its activity.

In addition to its potential as a drug target, LINC00402 has also been shown to be a potential biomarker for a variety of diseases. For example, studies have shown that LINC00402 is downregulated in a variety of cancer types and that it can be used as a diagnostic biomarker for these diseases. In addition, LINC00402 has also been shown to be downregulated in aging tissues and that it can be used as a potential therapeutic target for age-related diseases.

Overall, LINC00402 is a fascinating molecule that has the potential to be a drug target and biomarker. Its role in regulating the cell cycle and its involvement in a variety of cellular processes make it a promising target for small molecules or other therapeutic agents. Further research is needed to fully understand its mechanisms of action and its potential as a therapeutic agent.

Protein Name: Long Intergenic Non-protein Coding RNA 402

The "LINC00402 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00402 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets